Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Spin-Off AbbVie To Remain Close To Its Roots

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.

You may also be interested in...

J&J Under CEO Gorsky Will Remain Diverse But Be More Selective

New CEO Alex Gorsky outlines his vision for the healthcare giant in his first quarterly sales and earnings presentation to investors. Short-term priorities include restoring OTC drug supply and building pharmaceutical sales momentum.

Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria

Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.

The Ascent of Abbott: Humira Marketer Battles With FDA Over Biosimilars

Abbott Labs wasn’t considered a serious biologics manufacturer when the biosimilars pathway was first being debated. But with the arthritis treatment Humira now the world’s best-selling pharmaceutical brand, the company has assumed a leadership position just as the biosimilar opportunity is emerging. And what better way to use that new role than by launching an offensive strike against FDA?

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts